News

News 25.08.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”), today reported corporate highlights and financial...

News 18.08.2026 Schlieren, Switzerland – August 17, 2026 The combined leadership role will strengthen operational excellence, digitalization, and technology development as InSphero continues to grow and scale its organization. InSphero AG today announced the promotion of Olivier Frey, PhD, to the combined role of Chief Operating Officer (COO) and Chief Technology Officer (CTO). Previously Vice...

News 14.08.2026 Boehringer Ingelheim has acquired Evax AG, a Swiss biotech company focused on therapeutic vaccines to address significant unmet needs in horses, particularly for the treatment of allergic skin diseases. Allergies and dermatologic conditions in horses are common and have a significant impact on their health and well-being yet are very challenging to treat....

News 13.08.2026 Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability  Schlieren (Zurich), Switzerland, August 13, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial and operational results for the first half of 2026. Financial Highlights Total Medical Device sales...

News 10.08.2026 CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced that its fully-owned Swiss subsidiary, Proteomedix AG (“PMX”), has appointed Ralph Schiess, PhD to the PMX Board of Directors. The appointment was approved at the PMX Annual General Meeting of Shareholders held...